Other Clinical Trial - Plasma-Adapted First-Line Pembro In NSCLC

Status Active, not recruiting

Clinical Trial Summary

This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and use that information to determine whether patients should continue treatment with pembrolizumab or switch treatment to pembrolizumab in combination with chemotherapy. The names of the study drugs involved in this study are: - Pembrolizumab - Platinum doublet chemotherapy, which may include the following: - Carboplatin and pemetrexed - Carboplatin and paclitaxel The name of the blood test: - InVision (Inivata, Ltd.)

Clinical Trial Description

This is an open label, single institution, prospective pilot study. The purpose of this research study is to determine if a blood test, collected at different times during treatment, can be used to detect early response in patients being treated with pembrolizumab for lung cancer and use that information to determine whether patients should continue treatment with pembrolizumab or switch treatment to pembrolizumab in combination with chemotherapy. -The research study procedures include screening for eligibility and study treatment including evaluations approximately every 3 weeks. The names of the study drugs involved in this study are: - Pembrolizumab - Platinum doublet chemotherapy, which may include the following: - Carboplatin and pemetrexed - Carboplatin and paclitaxel The name of the blood test: - InVision- Inivata - This blood test that will help study how participants respond to the study treatment. --- - Blood will be collected for this test at a few time points, both before and after participants receive treatment on study. - Participants will be on the research study for up to 12 months. - It is expected that about 40 people will take part in this research study. ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Metastatic Non-Small Cell Lung Cancer
NSCLC Stage IV

Clinical Trial Details

NCT number	NCT04166487
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	January 13, 2020
Completion date	June 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05543330` - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC	Phase 1/Phase 2
Recruiting	`NCT04106180` - SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC	Phase 2
Recruiting	`NCT05215548` - Primary Tumor Resection With EGFR TKI for Stage IV NSCLC	Phase 2
Recruiting	`NCT04042558` - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	Phase 2
Completed	`NCT04507217` - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC	Phase 2
Recruiting	`NCT04467801` - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy	Phase 2
Active, not recruiting	`NCT04027647` - Phase 2 Study of Dacomitinib in NSCLC	Phase 2
Recruiting	`NCT04768491` - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Not yet recruiting	`NCT04492969` - Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
Recruiting	`NCT04116918` - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Terminated	`NCT03411473` - Study of AGEN1884 With Pembrolizumab in 1L NSCLC	Phase 2
Recruiting	`NCT03564197` - 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC	N/A
Not yet recruiting	`NCT06219317` - Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC	Phase 2
Not yet recruiting	`NCT04604470` - Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Recruiting	`NCT05132218` - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Not yet recruiting	`NCT04136535` - Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC	Phase 2
Completed	`NCT03184571` - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	Phase 2
Completed	`NCT06339554` - Alectinib-induced Endocrine Toxicity
Recruiting	`NCT04549428` - Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC	Phase 2
Recruiting	`NCT03647956` - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	Phase 2